CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Resignation of Dr. Andrew Pecora as Director
On December 28, 2016, Dr. Andrew Pecora resigned as a director of the board of directors (the “Board”) of Caladrius Biosciences, Inc. (the “Company” or “Caladrius”) effective December 28, 2016. Dr. Pecora’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases. CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information
CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session up +0.06 at 2.83 with 95,536 shares trading hands.
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases. CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information
CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session up +0.06 at 2.83 with 95,536 shares trading hands.
